

# A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma

<b>Submission date</b> 04/11/2023	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/03/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 07/04/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In this study the researchers are testing a drug called ginisortamab that blocks a protein called gremlin-1. Gremlin-1 is mainly found outside cancer cells and it stops the function of other proteins called bone morphogenetic proteins (BMPs). BMP proteins work by suppressing cancer cells as they occur but in cancer this mechanism has often been switched off. Blocking gremlin-1 with ginisortamab is expected to allow BMP protein function, and we hope this will change the way the cancer cells develop, making them more sensitive to other targeted treatments and/or chemotherapy.

The researchers are testing ginisortamab in two different settings (modules), in people with pancreatic ductal adenocarcinoma (PDAC) that has spread (metastatic). Module 1 will involve participants about to start first-line therapy of ginisortamab with standard-of-care chemotherapy, nab-paclitaxel and gemcitabine. Module 2 will involve participants whose tumours have either shrunk or not grown significantly with a first-line standard of care regimen (FOLFIRINOX [folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplatin], or nab-paclitaxel plus gemcitabine) after  $\geq 16$  weeks of treatment who will then be randomised to either i) maintenance therapy of ginisortamab in combination with another treatment called cobimetinib (which can help stop cancer cells from growing and may kill them by blocking two proteins called MEK1 and MEK2) or ii) observation only.

The four main aims of this clinical trial are to find out:

1. The best dose of ginisortamab to be given to participants along with nab-paclitaxel and gemcitabine (Module 1) or cobimetinib (Module 2).
2. More about potential side effects of ginisortamab when given with nab-paclitaxel and gemcitabine (Module 1) or cobimetinib (Module 2) and how they can be managed.
3. To see if adding ginisortamab to treatment improves the effectiveness of treatment.
4. What happens to ginisortamab inside the body and what effect it has on tumour samples.

### Who can participate?

Patients aged 18 years and over with metastatic PDAC

What does the study involve?

Both modules will start with a safety run-in, which aims to find the dose of ginisortamab that is best to give along with other treatments (nab-paclitaxel and gemcitabine, or cobimetinib). The dose of ginisortamab could be lowered from the starting dose in this part of the trial, if needed. After each safety run-in is completed, an expansion cohort will open using the best dose of ginisortamab from the safety run-in. We aim to recruit between 6 and 36 participants in each safety run-in and then up to 60 participants in each expansion cohort. Module 2 participants in the expansion cohort will be randomised (randomly allocated) to either i) maintenance therapy of ginisortamab in combination with cobimetinib or ii) observation only, where no medications are given as part of the trial.

What are the possible benefits and risks of participating?

Ginisortamab is a new drug that has not been tested in very many people. Possible risks and benefits are based on laboratory tests and experience with similar drugs. We do not yet have much information about the effects of ginisortamab in humans. Participants in the trial will be monitored closely to find out the effects of ginisortamab.

Where is the study run from?

Cancer Research UK

When is the study starting and how long is it expected to run for?

November 2023 to June 2029

Who is funding the study?

Cancer Research UK

Who is the main contact?

1. Prof. Jeff Evans, Jeff.Evans@ggc.scot.nhs.uk
2. Rashida Teladia, Rashida.Teladia@cancer.org.uk
3. Sarah Potter, Sarah.Potter@cancer.org.uk

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-ginisortamab-for-pancreatic-cancer-that-has-spread#undefined>

## Contact information

**Type(s)**

Scientific

**Contact name**

Miss Rashida Teladia

**Contact details**

2 Redman Place

London

United Kingdom

E20 1JQ

+44 (0)203 469 6878

Rashida.Teladia@cancer.org.uk

**Type(s)**

Scientific

**Contact name**

Mrs Sarah Potter

**Contact details**

2 Redman Place  
London  
United Kingdom  
E20 1JQ  
+44 (0)203 469 8957  
Sarah.Potter@cancer.org.uk

**Type(s)**

Principal investigator

**Contact name**

Prof Jeff Evans

**Contact details**

1053 Great Western Road  
Glasgow  
United Kingdom  
G12 0YN  
+44 (0)141 330 ext 4171  
jeff.evans@beatson.gla.ac.uk

## Additional identifiers

**Integrated Research Application System (IRAS)**

1007925

**Protocol serial number**

CRUKD/24/002

## Study information

**Scientific Title**

A Cancer Research UK Phase II open-label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously i) with first-line standard of care nab-paclitaxel and gemcitabine, or ii) in combination with cobimetinib maintenance therapy

**Study objectives**

Primary objectives:

Module 1:

1. To assess the safety and toxicity profile of ginisortamab when given with standard of care (SoC) nab-paclitaxel and gemcitabine first-line therapy.
2. To identify a recommended dose of ginisortamab when given with SoC nab-paclitaxel and

gemcitabine first-line therapy.

3. To document anti-tumour activity of ginisortamab when given with SoC nab-paclitaxel and gemcitabine first-line therapy.

Module 2:

1. To assess the safety and toxicity profile of ginisortamab when given in combination with cobimetinib as maintenance therapy.

2. To identify a recommended dose of ginisortamab when given in combination with cobimetinib as maintenance therapy.

3. To document possible anti-tumour activity of ginisortamab when given in combination with cobimetinib as maintenance therapy in participants with ongoing response or disease stabilisation after  $\geq 16$  weeks of a SoC regimen.

Secondary objectives:

Module 1:

1. To further describe anti-tumour activity of ginisortamab when given with SoC nab-paclitaxel and gemcitabine first-line therapy.

2. To investigate pharmacokinetic (PK) parameters of ginisortamab in participants when given with SoC nab-paclitaxel and gemcitabine first-line therapy.

Module 2:

1. To further describe anti-tumour activity of ginisortamab when given in combination with cobimetinib as maintenance therapy in participants with ongoing response or disease stabilisation after  $\geq 16$  weeks of a SoC regimen.

2. To investigate PK parameters of ginisortamab in participants when given in combination with cobimetinib as maintenance therapy (Arm A).

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 04/01/2024, London - West London & GTAC (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, United Kingdom; +44 (0)207 104 8098; westlondon.rec@hra.nhs.uk), ref: 23/LO/0662

## **Study design**

Multi-centre, open-label, Phase II non-randomized (Module 1) and randomized (Module 2) trial

## **Primary study design**

Interventional

## **Study type(s)**

Efficacy, Safety

## **Health condition(s) or problem(s) studied**

Metastatic pancreatic ductal adenocarcinoma

## **Interventions**

Current interventions as of 07/04/2026:

Module 1: Participants will receive ginisortamab (investigational medicinal product [IMP])

administered by 30 ( $\pm 10$ )-minute intravenous (IV) infusion once every 2 weeks. Participants will

also receive standard of care (SoC) treatment of nab-paclitaxel and gemcitabine (non-IMPs). The starting dose of ginisortamab administered will be 2000 mg, which may be de-escalated to 1000 or 500 mg, and SoC treatment will be given in accordance with the recommended dose and schedule. Participants may receive up to twelve 28-day cycles and be followed for up to 6 months after their last dose. Participants deemed to be benefitting from ginisortamab, who are not experiencing any severe adverse reactions, may be considered for treatment beyond 12 cycles.

Module 2 Arm A: Participants randomised to this arm will receive ginisortamab (IMP) by 30 ( $\pm$ 10)-minute IV infusion once every 2 weeks, in combination with cobimetinib (IMP). The starting dose of ginisortamab administered will be 2000 mg, which may be de-escalated to 1000 or 500 mg, and cobimetinib will be administered orally as 60 mg once daily in 28-day cycles. Cobimetinib should be taken for 21 consecutive days, followed by a 7-day break. Participants deemed benefitting from ginisortamab in combination with cobimetinib, who are not experiencing any severe adverse reactions, may be considered for treatment beyond 12 cycles.

Module 2 Arm B: Participants randomised to this arm will be under observation only, with no IMP administered.

Previous interventions:

Module 1: Participants will receive ginisortamab (investigational medicinal product [IMP]) administered by 30 ( $\pm$ 10)-minute intravenous (IV) infusion once every 2 weeks. Participants will also receive standard of care (SoC) treatment of nab-paclitaxel and gemcitabine (non-IMPs). The starting dose of ginisortamab administered will be 2000 mg, which may be de-escalated to 1000 or 500 mg, and SoC treatment will be given in accordance with the recommended dose and schedule. Participants may receive up to twelve 28-day cycles and be followed for up to 6 months after their last dose. Participants deemed to be benefitting from ginisortamab may be considered for treatment beyond 12 cycles.

Module 2 Arm A: Participants randomised to this arm will receive ginisortamab (IMP) by 30 ( $\pm$ 10)-minute IV infusion once every 2 weeks, in combination with a MEK inhibitor (IMP). The starting dose of ginisortamab administered will be 2000 mg, which may be de-escalated to 1000 or 500 mg, and the MEK inhibitor dose and schedule will be based on the choice of agent. Further details will be provided once the MEK inhibitor is confirmed.

Module 2 Arm B: Participants randomised to this arm will be under observation only, with no IMP administered.

## **Intervention Type**

Drug

## **Phase**

Phase II

## **Drug/device/biological/vaccine name(s)**

Ginisortamab

## **Primary outcome(s)**

Module 1:

1. Frequency of adverse events (AEs) considered at least possibly related to ginisortamab, and the number of Grade 3, 4 and 5 AEs at least possibly related to ginisortamab for up to an initial

maximum of 12 cycles (~1 year) and no more than 24 cycles (~2 years). AEs, including relatedness, seriousness and severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, will be assessed by the Investigator. Evaluation of this endpoint will occur once the last participant enrolled to Module 1 has received up to 24 cycles (~2 years) of ginisortamab.

2. Recommended dose of ginisortamab for use with standard of care (SoC) nab-paclitaxel and ginisortamab following the review of all available clinically relevant data, including but not limited to toxicity, efficacy and PK data by the Sponsor and Investigators. Evaluation of this endpoint will occur once all participants in the module have completed the safety run-in period (28 days) and all relevant data have been collected.

3. Progression-free survival (PFS), defined as the time from the date of starting ginisortamab plus SoC nab-paclitaxel and gemcitabine to the date of disease progression or date of death, whichever occurs first. Response will be assessed at baseline, at the end of every 8 weeks and at end of treatment. Participants who withdraw from the trial due to reasons other than progression will be followed up for survival for up to 12 months after the date upon which the last participant enrolled to Module 1 receives their first dose of ginisortamab.

4. Disease control rate (DCR), defined as the proportion of participants who achieve a best response of complete response (CR), partial response (PR), or SD of duration  $\geq 16$  weeks, evaluated according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1. Response will be assessed at baseline, at the end of every 8 weeks and at end of treatment.

#### Module 2:

5. Frequency of AEs considered at least possibly related to IMP(s), and the number of Grade 3, 4 and 5 AEs at least possibly related to IMP(s). AEs, including relatedness, seriousness and severity according to NCI CTCAE Version 5.0, will be assessed by the Investigator. Further details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

6. Recommended dose of ginisortamab for use in combination with cobimetinib, following the review of all available clinically relevant data, including but not limited to toxicity, efficacy and PK data by the Sponsor and Investigators. Evaluation of this endpoint will occur once all participants in the module have completed the safety run-in period (28 days) and all relevant data have been collected.

7. PFS 1, defined as the time from date of randomisation to date of disease progression or date of death, whichever occurs first. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

#### **Key secondary outcome(s)**

##### Module 1:

1. Overall survival (OS), calculated from the date of starting ginisortamab plus SoC nab-paclitaxel and gemcitabine to the date of death. Participant status will be reviewed throughout the trial and for up to 12 months after the date upon which the last participant enrolled to Module 1 receives their first dose of ginisortamab.

2. Overall response rate (ORR), defined as the proportion of participants who achieve a best response of CR or PR according to RECIST Version 1.1. Response will be assessed at baseline, at the end of every 8 weeks and at end of treatment.

3. Duration of response (DoR), defined as the time from the date of the first confirmed CR or PR according to RECIST Version 1.1 to the date of disease progression. Response will be assessed at baseline, at the end of every 8 weeks and at end of treatment. Participants who withdraw from the trial due to reasons other than progression will be followed up for survival for up to 12 months after the date upon which the last participant enrolled to Module 1 receives their first dose of ginisortamab.

4. Time to next therapy (TTNT), defined as the time from the date of starting ginisortamab plus SoC nab-paclitaxel and gemcitabine to the date of starting the next treatment regimen following discontinuation of trial treatment in this trial. Participant status will be reviewed throughout the trial and for up to 12 months after the date upon which the last participant enrolled to Module 1 receives their first dose of ginisortamab.

5. PK parameters for ginisortamab when given with SoC nab-paclitaxel and gemcitabine, including maximum observed plasma concentration (C<sub>max</sub>), area under the concentration-time curve (AUC), terminal elimination half-life (T<sub>1/2</sub>), volume of distribution at steady state (V<sub>ss</sub>), clearance (CL) and trough concentration (C<sub>trough</sub>) for the safety run-in, and C<sub>max</sub> and C<sub>trough</sub> for the dose expansion. Samples for PK analysis will be taken at up to 17 timepoints across Cycles 1 and 2 and up to 9 timepoints thereafter.

#### Module 2:

6. PFS 2: defined as the time from the date of starting a first-line SoC regimen to the date of disease progression or date of death, whichever occurs first. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

7. OS, calculated from the date of starting a first-line SoC regimen to the date of death. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

8. ORR, defined as the proportion of participants who achieve a best response of CR or PR according to RECIST Version 1.1. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

9. DCR, defined as the best response of CR, PR or SD according to RECIST Version 1.1 at 3, 6, 9 and 12 months after randomisation. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

10. DoR 1, defined as the time from the date of the first confirmed CR or PR according to RECIST Version 1.1 to the date of disease progression. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

11. DoR 2: defined as the time from the date of randomisation to the date of disease progression, measured in participants who had CR/PR at randomisation. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

12. Time to next therapy, defined as the time from the date of randomisation to the date of starting the next treatment regimen. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

13. PK parameters for ginisortamab when given in combination with cobimetinib, including C<sub>max</sub>, AUC, T<sub>1/2</sub>, V<sub>ss</sub>, CL and C<sub>trough</sub> for the safety run-in, and C<sub>max</sub> and C<sub>trough</sub> for the expansion. Details of the evaluation of this endpoint will be provided once the study design for Module 2 has been finalised.

#### Completion date

01/06/2029

## Eligibility

#### Key inclusion criteria

Current inclusion criteria as of 07/04/2026:

Applicable to All Trial Participants:

1. Written (signed and dated) informed consent, and capable of co-operating with IMP (and SoC) administration and follow-up.
2. Histologically or cytologically confirmed diagnosis of PDAC with metastatic disease.

3. Consent for pre- and on-treatment tumour biopsy samples for assessment of molecular markers, including but not limited to, SMAD4 and gremlin-1. Pre- and on-treatment tumour samples are mandatory in the first instance. These tumour samples may become optional as considered appropriate by the Sponsor and Investigators based on a review of emerging data during the trial. Participants must have disease amenable to biopsy as deemed safe by the Investigator.
4. Measurable disease according to RECIST Version 1.1.
5. Eastern Cooperative Oncology Group performance status of  $\leq 1$ .
6. Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial.
7. Aged 18 years or over at the time consent is given.

#### Module 2 – Additional Inclusion Criteria:

1. Investigator determination that the clinical interests of the participant are best served by stopping SoC induction therapy (FOLFIRINOX, or nab-paclitaxel plus gemcitabine) after attainment of a best response of  $\geq$  SD.
2. At least ongoing SD or response (CR/PR) after  $\geq 16$  weeks of treatment with a SoC first-line induction regimen (FOLFIRINOX, or nab-paclitaxel plus gemcitabine).  
- Ongoing SD or response must be confirmed on the trial baseline scan.
3. Not a candidate for PARP inhibitor maintenance therapy.

#### Previous inclusion criteria:

##### Module 1:

1. Written (signed and dated) informed consent, and capable of co-operating with IMP (and SoC) administration and follow-up.
2. Histologically or cytologically confirmed diagnosis of PDAC with metastatic disease.
3. Consent for pre- and on-treatment tumour biopsy samples for assessment of molecular markers, including but not limited to, SMAD4 and gremlin-1. Pre- and on-treatment tumour samples are mandatory in the first instance. These tumour samples may become optional as considered appropriate by the Sponsor and Investigators based on a review of emerging data during the trial. Participants must have disease amenable to biopsy as deemed safe by the Investigator.
4. Measurable disease according to RECIST Version 1.1.
5. Eastern Cooperative Oncology Group performance status of  $\leq 1$ .
6. Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial.
7. Aged 18 years or over at the time consent is given.

#### **Participant type(s)**

Patient

#### **Healthy volunteers allowed**

No

#### **Age group**

Mixed

#### **Lower age limit**

18 years

#### **Upper age limit**

150 years

## Sex

All

## Total final enrolment

0

## Key exclusion criteria

Current exclusion criteria as of 07/04/2026:

Applicable to All Trial Participants:

1. Previous radiotherapy (except palliative) within 6 months prior, chemotherapy, investigational therapy for metastatic PDAC, other anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of IMP.
2. Live vaccinations will not be permitted within 28 days before trial enrolment.
3. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.
4. Prior neo-adjuvant, peri-operative, or adjuvant chemotherapy for non-metastatic pancreatic adenocarcinoma with curative intent unless recurrent (i.e. metastatic) disease is documented more than 6 months since the last dose of systemic therapy.
5. Clinically significant/symptomatic third space fluid accumulation (e.g. ascites or pleural effusion).
6. Ongoing toxic manifestations of previous treatments considered by the Investigator to make the patient unsuitable for the trial.
7. Brain or leptomeningeal metastases.
8. Clinically significant ongoing pulmonary disease, including but not limited to interstitial lung disease, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis.
9. History of pulmonary embolism or deep vein thrombosis unless continuing anticoagulant treatment as clinically indicated.
10. Major thoracic or abdominal surgery from which the patient has not yet recovered.
11. At high medical risk because of non-malignant systemic disease, including active uncontrolled infection. Patients with previous HCV exposure but no current infection are eligible to participate. Any uncontrolled active systemic infection requiring systemic IV treatment that was completed  $\leq 7$  days before Cycle 1 Day 1.
12. Known to be serologically positive for HBV, HCV or HIV. Patients who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have an undetectable HCV RNA by PCR or HBV DNA (by PCR) that is  $< 500$  IU/mL before enrolment. Patients who are HBV core antibody positive should receive SoC anti-viral therapy during trial treatment.
13. Known hypersensitivity to any of the ingredients/excipients in the IMP to be administered.
14. Significant cardiovascular disease, defined as:
  - 14.1. History of congestive heart failure requiring therapy (New York Heart Association III or IV) or LVEF  $< 40\%$  (moderate or severe);
  - 14.2 History of unstable angina pectoris or myocardial infarction within 6 months prior to trial entry, or current poorly controlled angina (symptoms weekly or more);
  - 14.3 Presence of symptomatic or severe valvular heart disease (severe by local echocardiographic criteria or American Heart Association/American College of Cardiology Stage C or D);
  - 14.4 History of a clinically significant cardiac arrhythmia within 6 months prior to trial entry (asymptomatic atrial fibrillation or asymptomatic first-degree heart block is permitted).
15. Baseline corrected QTcF  $> 450$  ms measured on triplicate ECG (if an average QTcF of  $> 450$  ms then the patient is ineligible).

16. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase II trial of ginisortamab. Participation in an observational trial or interventional clinical trial that does not involve administration of an IMP and that would not place an unacceptable burden on the patient, in the opinion of the Investigator, would be acceptable.

17. Current or prior malignancy that could affect safety or efficacy assessment of the IMP or compliance with the protocol or interpretation of results. Patients with curatively treated non-melanoma skin cancer, non-muscle-invasive bladder cancer, or carcinomas-in-situ are generally eligible.

18. Patients with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy, or who require only hormonal therapy and have had normal prostate-specific antigen for >1 year prior to the start of therapy, are eligible for participation in the trial.

19. Patients with any congenital or acquired immunodeficiency syndrome or who are receiving immunosuppressive therapy (including any dose of systemic corticosteroids), or who are immunosuppressed post-organ transplant. However, patients receiving inhaled corticosteroids and patients with a history of allergy (other than anaphylaxis) are eligible, as are patients with a history of autoimmune disease.

20. Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the patient.

#### Module 1 – Additional Exclusion Criteria:

1. Prior chemotherapy for unresectable disease

#### Module 2 – Additional Exclusion Criteria:

1. More than one systemic chemotherapy regimen given in the metastatic setting.

2. Clinically significant ophthalmoscopic findings at the time of screening or history of ophthalmological findings, such as retinal detachment, severe visual impairment, central serous chorioretinopathy, neovascular retinopathy, or retinopathy of prematurity.

3. History of retinal vein occlusion.

4. Any strong inhibitors or inducers of CYP3A (including supplements) within 7 days prior to initiation of Cycle 1 Day 1, and during study treatment for participants in the safety run-in and expansion Arm A.

5. LVEF <40%. This measurement should be performed to confirm the participant's eligibility to participate in the trial.

6. Participant is unable to swallow cobimetinib intact, without chewing or crushing the tablets (as per the dosing schedule) or is known to have dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or GI absorption of drugs administered orally.

#### Applicable to Participants in Module 1 and Module 2:

1. Female patients of childbearing potential. However, those patients of childbearing potential who are not already pregnant or breastfeeding, or who agree to discontinue breastfeeding, or who meet the following points are considered eligible:

1.1. Have a negative highly sensitive serum pregnancy test within 7 days before Day 1 and either:

1.1.1. Agree to one form of highly effective contraception;

1.1.2. Or agree to sexual abstinence.

1.2. Effective from the date of the negative pregnancy test, throughout the trial and for 6 months after the last administration of IMP or SoC chemotherapy agents (whichever component is administered last).

1.3. Participants randomised to Module 2 expansion Arm B do not need to adhere to the on-trial or post-trial contraception requirements.

3. Male patients with partners of childbearing potential or who are pregnant or breastfeeding. However, those patients who meet the following points are considered eligible:

3.1. Agree to take measures not to father children by using a barrier method of contraception

(condom) or sexual abstinence effective from the date of the first administration of IMP and SoC chemotherapy agents, throughout the trial and for 6 months (Module 1) or for 2 weeks (Module 2) after the last administration of IMPs (whichever component is administered last for both Modules).

3.2. Non-vasectomised male patients must also be willing to ensure that any partner who is of childbearing potential uses a highly effective method of contraception or agrees to sexual abstinence after the last administration of IMPs (whichever component is administered last for both Modules).

3.3. Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent exposure of the foetus or neonate (for 2 weeks for Module 2) after the last administration of IMPs (whichever component is administered last for both Modules).

3.3.1. All male patients must refrain from donating sperm throughout the trial and for 6 months (Module 1) or 2 weeks (Module 2) after the last administration of IMPs (whichever component is administered last).

3.3.2. Participants randomised to Module 2 expansion Arm B do not need to adhere to the on-trial or post-trial contraception requirements.

Previous exclusion criteria:

Module 1 exclusion criteria:

1. Previous radiotherapy (except palliative) within 6 months prior, chemotherapy, investigational therapy for metastatic PDAC, other anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of IMP.

2. Live vaccinations will not be permitted within 28 days before trial enrolment.

3. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.

4. Prior neo-adjuvant, peri-operative, or adjuvant chemotherapy for non-metastatic pancreatic adenocarcinoma with curative intent unless recurrent (i.e. metastatic) disease is documented more than 6 months since the last dose of systemic therapy.

5. Clinically significant/symptomatic third space fluid accumulation (e.g. ascites or pleural effusion).

6. Ongoing toxic manifestations of previous treatments considered by the Investigator to make the patient unsuitable for the trial.

7. Brain or leptomeningeal metastases.

8. Clinically significant ongoing pulmonary disease, including but not limited to interstitial lung disease, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis.

9. History of pulmonary embolism or deep vein thrombosis unless continuing anticoagulant treatment as clinically indicated.

10. Female patients of childbearing potential. However, those patients of childbearing potential who are not already pregnant or breastfeeding, or who agree to discontinue breastfeeding, or who meet the following points are considered eligible:

11. Have a negative highly sensitive serum pregnancy test within 7 days before Day 1 and either:

11.1. Agree to one form of highly effective contraception

11.2. Or agree to sexual abstinence

Effective from the date of the negative pregnancy test, throughout the trial and for 6 months after the last administration of IMP or SoC chemotherapy agents (whichever component is administered last).

11.3. Male patients with partners of childbearing potential or who are pregnant or breastfeeding. However, those patients who meet the following points are considered eligible:

11.3.1. Agree to take measures not to father children by using a barrier method of contraception (condom) or sexual abstinence effective from the date of the first administration of IMP and SoC chemotherapy agents, throughout the trial and for 6 months after the last administration of IMP or SoC chemotherapy agents (whichever component is administered last).

11.3.2. Non-vasectomised male patients must also be willing to ensure that any partner who is of childbearing potential uses a highly effective method of contraception or agrees to sexual abstinence for the same duration.

11.3.3. Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent exposure of the foetus or neonate.

12. Major thoracic or abdominal surgery from which the patient has not yet recovered.

13. At high medical risk because of non-malignant systemic disease, including active uncontrolled infection.

14. Known hypersensitivity to any of the ingredients/excipients in the IMP to be administered.

**Date of first enrolment**

18/03/2024

**Date of final enrolment**

31/10/2028

## **Locations**

**Countries of recruitment**

United Kingdom

England

Scotland

Germany

Norway

Spain

**Study participating centre**

**Beatson West of Scotland Cancer Centre**

1053 Great Western Road

Glasgow

Scotland

G12 0YN

**Study participating centre**

**UCLH**

250 Euston Road

London

England

NW1 2PQ

**Study participating centre**  
**Western General Hospital**  
Crewe Road South  
Edinburgh  
Scotland  
EH4 2XU

**Study participating centre**  
**Aberdeen Royal Infirmary**  
Foresterhill Road  
Aberdeen  
Scotland  
AB25 2ZN

**Study participating centre**  
**Guys Hospital**  
Guys Hospital  
Great Maze Pond  
London  
England  
SE1 9RT

**Study participating centre**  
**The Christie**  
Wilmslow Road  
Withington  
Manchester  
England  
M20 4BX

## **Sponsor information**

**Organisation**  
Cancer Research UK

**ROR**  
<https://ror.org/054225q67>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be available upon request. Data from this trial and the final clinical study protocol will be submitted to a public registry and will be available immediately following publication, with no end date. Individual deidentified participant data that underlie the results reported will be shared with researchers whose proposed use of the data is approved by a review committee of the Sponsor. All requests made within 5 years from end of trial will be considered; requests made subsequently will be considered where possible. Requests should be submitted to [drugdev@cancer.org.uk](mailto:drugdev@cancer.org.uk).

**IPD sharing plan summary**

Available on request